RNAZ — Transcode Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $5.49m
- $0.58m
- 10
- 28
- 23
- 10
Annual cashflow statement for Transcode Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.607 | -2.34 | -6.84 | -17.6 | -18.5 |
| Depreciation | |||||
| Non-Cash Items | 0.103 | 1.54 | 1.13 | 0.365 | 1.43 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.005 | 0.31 | 0.402 | 1.34 | -1.08 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.509 | -0.493 | -5.27 | -15.8 | -18.1 |
| Capital Expenditures | — | — | -0.255 | -0.101 | -0.036 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | 0.003 | 0 | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | — | — | -0.252 | -0.101 | -0.036 |
| Financing Cash Flow Items | 0 | -0.073 | -0.832 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.5 | 1.12 | 25.5 | 0.006 | 15.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.009 | 0.624 | 20 | -15.9 | -2.2 |